Skip to main content

JOHNSON & JOHNSON

For the period ended Dec 29, 2024. Filed Feb 13, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 13, 2025

JNJ$280.78-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated statements of comprehensive income

Johnson & Johnson and subsidiaries consolidated statements of comprehensive income

202420232022
Net earnings$14,06635,15317,941
Other comprehensive income (loss), net of tax
Foreign currency translation1,708(3,221)(1,796)
Securities:
Unrealized holding gain (loss) arising during period226(24)
Reclassifications to earnings———
Net change226(24)
Employee benefit plans:
Prior service credit (cost), net of amortization(154)(149)(160)
Gain (loss), net of amortization541(1,183)1,854
Consumer settlement/ curtailment—23—
Effect of exchange rates62(90)111
Net change449(1,399)1,805
Derivatives & hedges:
Unrealized gain (loss) arising during period(511)422454
Reclassifications to earnings(862)(569)(348)
Net change(1,373)(147)106
Other comprehensive income (loss)786(4,741)91
Comprehensive income$14,85230,41218,032

The tax cost/(benefit) effects in other comprehensive income for the fiscal years 2024, 2023 and 2022 respectively: Foreign Currency Translation; $(1.1) billion, $797 million and $(460) million; Employee Benefit Plans: $86 million, $(289) million and $461 million, Derivatives & Hedges: $(365) million, $(39) million and $30 million.

Amounts presented for 2023 and 2022 have not been recast to exclude discontinued operations

46

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.